DUPILUMAB; UPADACITINIB (Review of cost-effectiveness of drugs for atopic dermatitis)

Information current as at: 1 June 2026

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Dupixent®
  • Rinvoq®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
Sanofi-Aventis Australia Pty Ltd; AbbVie Pty Ltd
Condition/indication:
(therapeutic use)
  • Severe atopic dermatitis
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
Other business (Matters arising/Matters outstanding)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for:
November 2023 PBAC meeting
Opportunity for consumer comment:
Open 26/07/2023 and close 20/09/2023 (see PBS Website)
PBAC meeting:
Held on 01/11/2023
PBAC outcome published:
Advice Provided (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
PBAC Public Summary Documents – November 2023
Case ID
a869
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19